Heart disease is becoming younger. What technologies can help prevent tragedies?
Today, the 35-year-old actor Gao Yixiang has a heart attack, and his life is regrettable at the last moment.
Cardiovascular disease is a major disease that deprives human life. Many celebrities such as Dr. Zhang Rui, the founder of Dr. Chunyu, the sketch actor Gao Xiumin, and the oil painter Chen Yifei, all died due to sudden heart attack.
According to the Report on Cardiovascular Diseases in China, the prevalence and mortality of cardiovascular disease in China are still on the rise. Among them, the current number of cardiovascular disease patients reaches 290 million, with a mortality rate higher than that of tumors and other diseases, accounting for more than 40% of the deaths caused by residents.
In order to prevent and treat heart disease, the medical and industrial circles have made many efforts. Organized companies in the heart field at home and abroad to see what “new technologies” care for heart health. May science and technology progress a little bit more and tragedies happen a little less.
Smart wearable electrocardiograph
Xuhong Medical is developing a real-time cardiac care product “Zhixintie”, which can monitor vascular and structural heart problems such as hypertension, coronary heart disease, myocarditis, make abnormal alarms in real time, and accurately locate the heart rhythm Disturbance of disease location and real-time diagnosis.
Xuhong Medical’s monitoring report can also be used directly for medical treatment and diagnosis. It has cooperated with the First Affiliated Hospital of Dalian Medical University and several top three hospitals in Beijing.
Image from Xuhong Medical
Zhengxin Medical team also developed CardioGuard, a smart wearable ECG system. This product uses a flexible patch design that can be continuously monitored for a long time and can detect 54 types of arrhythmias in 12 categories.
It is reported that the early research and development team of Zhengxin Medical came from the United States, and the early team continued to work in Seattle.The domestic team conducted research in Suzhou, Beijing, and Yantai.
Image from Zhengxin Medical Official Website
iRhythm in the United States has launched a wearable skin patch that uses artificial intelligence technology to monitor heart health for 24 hours. Users don’t need to go to the hospital to live normally at home, they can use this skin patch to perform continuous monitoring for up to 14 days, replacing the traditional ambulatory ECG monitoring outside the hospital. The monitoring report finally obtained through machine deep learning and analysis by technical staff can be directly used for the diagnosis of arrhythmia.
iRhythm’s wearable skin patch has been approved by the FDA, and is covered by US medical insurance and major commercial insurance. It can be compatible with the EHR system of various clinics.
Image from iRhythm
Cardiac interventional devices
China is a country with a high incidence of heart valve disease. Traditional treatment requires thoracotomy, which is extremely risky. According to statistics, of the 12 million patients with heart valve disease in the world, more than 2 million are in China.
Cardiac interventional therapy is a new technology for diagnosing and treating cardiovascular diseases. It does not require thoracotomy. Under the guidance of imaging methods, it passes through the body’s blood vessels and uses certain instruments to deliver the catheter to the lesion. Diagnosis and treatment of cardiac catheterization techniques.
At present, cardiac interventional therapy devices have become one of the most popular directions for medical device research and development in the world, and are predicted to be one of the ten most influential medical innovations in 2019. High-end consumable products are also developing rapidly. Medical device giants Medtronic, Abbott, and Edwards Life Sciences have entered this field. Among them, applicationsThe localization rate of the most mature coronary stent has exceeded 75%, and import substitution has basically been completed.
Abbott’s flagship platform, the MitraClip-based transceiver splicing device, has been approved by the FDA for the treatment of mitral regurgitation. MitraClip is the world’s first minimally invasive mitral valve repair device, which can help relieve symptoms immediately, and minimally invasive enables patients to be discharged quickly.
Abbott MitraClip
Similarly for mitral regurgitation disease, China’s Hanyu Medical is developing an interventional medical device ValveClamp. The operation does not require thoracotomy and heart incision, and no cardiac arrest. Only a 3 cm incision is made in the anterior region of the heart, and the heart is punctured into the instrument for surgical operation. Invasive surgery. ”
Product prototype of ValveClamp
AI Cardiovascular Medical Image Recognition
Many companies are using artificial intelligence to help doctors diagnose cardiovascular blood flow conditions.
Heart Century’s core product is ct-FFR, which can use AI technology to help realize “4D” visualization of the heart and assist in the diagnosis of coronary heart disease.
If the doctor finds a disease, send CCTA images to Xin Century for analysis by AI algorithms, hemodynamic calculation simulation, image processing, and trained analysts. Finally, a personalized, color-coded 3D model of the patient’s coronary artery is formed, and the functional information of each blood vessel is also provided based on the 3D model.
Xin Century’s current development progress is: it has established clinical cooperation with 7 hospitals, and its partners are Fuwai Hospital, TEDA International Cardiovascular Hospital, Chaoyang Hospital, Shaw Run Hospital, Qilu Hospital, Tongren Hospital, Ha First Hospital of Medical University. The product is completed in 2019Product clinical, 2020 market launch.
Heart Century ct-FFR
HeartFlow company in California can be regarded as the leader in the ct-FFR industry. Doctors only need to upload CT data of coronary heart disease, and the HeartFlow platform can calculate the hemorrhage flow reserve score by scanning the 3D aorta and heart model. A blood flow model of the heart was established to evaluate the vascular blood flow of coronary heart disease in a non-invasive manner.
HeartFlow’s technology has obtained European CE certification in 2011 and US FDA approval in 2014.
HeartFlow
Ruixin Smart Medical has also developed a whole set of diagnostic software to evaluate the function of cardiovascular blood supply. Only the CT image of the patient’s heart can be used to accurately calculate the blood supply function of the blood vessel and generate a diagnostic report.
CoronaryDoc, a cardiovascular AI diagnostic product of Shukun Technology, can realize the “Polaride” of coronary diagnostic reports-from the patient’s original CTA image input to the output of intelligent structured reports that meet clinical standards, the entire process is fully automated In 30 seconds, it can solve the complete medical imaging diagnosis scene from shooting to reporting.
CoronaryDoc can achieve more complex scene decision-making for multiple targets, such as accurate extraction of coronary arteries and myocardium, accurate reconstruction of myocardial bridges, and 100% accurate diagnosis of coronary stenosis in patients with muscular bridges. Multi-objective decision-making also places higher requirements on algorithm accuracy and data quality.
The picture is from the official website of Shukun Technology
Cardiovascular disease has brought many problems to human health, is the focus of medical research, and is also the focus of attention of technology companies. The above are some related companies that have been sorted out, and there are more participants in the industry. This is using their wisdom to create better diagnostic technology.
Further reading:
Gao Yixiang’s sudden death is regrettable. How should we prevent sudden death?